Alnylam Pharmaceuticals
ALNY
#645
Rank
S$41.61 B
Marketcap
$322.64
Share price
-6.73%
Change (1 day)
40.67%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -S$0.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$2.09 Billion. In 2023 the company made an earning of -S$0.42 Billion, an increase over its 2022 earnings that were of -S$1.31 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$0.25 Billion-41.78%
2023 -S$0.42 Billion-67.84%
2022 -S$1.31 Billion36.93%
2021 -S$0.96 Billion-8.04%
2020 -S$1.04 Billion-15.66%
2019 -S$1.23 Billion12.23%
2018 -S$1.1 Billion62.91%
2017 -S$0.68 Billion17.78%
2016 -S$0.57 Billion43.44%
2015 -S$0.4 Billion60.69%
2014 -S$0.25 Billion98.2%
2013 -S$0.13 Billion
2011 -S$73.53 Million27.48%
2010 -S$57.68 Million-10.92%
2009 -S$64.75 Million95.77%
2008 -S$33.08 Million
2006 -S$52.98 Million-9.13%
2005 -S$58.31 Million34.74%
2004 -S$43.28 Million36.79%
2003 -S$31.64 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$0.71 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$6.66 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
S$83.45 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.33 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$46.95 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
S$17.07 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$9.93 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
S$1.10 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel